Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-throughput screen reveals purinergic receptor as a therapeutic target in circadian β-cell failure

ABSTRACT: High-throughput screen reveals purinergic receptor as a therapeutic target in circadian β-cell failure

PROVIDER: PRJNA773959 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16550148_1.fastq.gz	Fastqsanger.gz
	SRR16550148_2.fastq.gz	Fastqsanger.gz
	SRR16550149_1.fastq.gz	Fastqsanger.gz
	SRR16550149_2.fastq.gz	Fastqsanger.gz
	SRR16550150_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

High-throughput screen reveals purinergic receptor as a therapeutic target in circadian β-cell failure

Project description:We report a screen of 2,640 pharmacologically-active compounds in clock-deficient pancreatic β cells and reveal a mechanism by which ivermectin induces insulin secretion and regulates transcription in wild type and P2ry1 receptor knockout BetaTC6 β-cell lines by mRNA-seq.

2021-11-03 | GSE186469 | GEO

Single-cell RNA sequencing reveals distinct transcriptional features of the purinergic signaling in mouse trigeminal ganglion

Project description:Trigeminal ganglion (TG) is the first station of sensory pathways in the orofacial region. The TG neurons communicate with satellite glial cells (SGCs), macrophages and other cells forming a functional unit that is responsible for processing of orofacial sensory information. Purinergic signaling, one of the most widespread autocrine and paracrine pathways, plays a crucial role in intercellular communication. The multidirectional action of purinergic signaling in different cell types contributes to the neuromodulation and orofacial sensation. To fully understand the purinergic signaling in these processes, it is essential to determine the shared and unique expression patterns of genes associated with purinergic signaling in different cell types. Here, we performed single-cell RNA sequencing of 22,969 cells isolated from normal mouse TGs. We identified 18 distinct cell populations, including 6 neuron subpopulations, 3 glial subpopulations, 7 immune cell subpopulations, fibroblasts, and endothelial cells. We also revealed the transcriptional features of genes associated with purinergic signaling, including purinergic receptors, extracellular adenosine triphosphate (eATP) release channels, eATP metabolism-associated enzymes, and eATP transporters) in each cell type. Our results have important implications for understanding and predicting the cell type-specific roles of the purinergic signaling in orofacial signal processing in the trigeminal primary sensory system.

2022-10-12 | GSE213105 | GEO

Therapeutic miR-132 inhibition reverses heart failure

Project description:Despite some success of pharmacotherapies targeting primarily neurohormonal dysregulation, heart failure is a growing global pandemic with increasing burden. Treatments that improve the disease by reversing heart failure at the cardiomyocyte level are lacking. MicroRNAs (miRNA) are transcriptional regulators of gene expression, acting through complex biological networks, and playing thereby essential roles in disease progression. Adverse structural remodelling of the left ventricle due to myocardial infarction (MI) is a common pathological feature leading to heart failure. We previously demonstrated increased cardiomyocyte expression of the miR-212/132 family during pathological cardiac conditions. Transgenic mice overexpressing the miR-212/132 cluster (miR-212/132-TG) develop pathological cardiac remodelling and die prematurely from progressive HF. Using both knockout and antisense strategies, we have shown miR-132 to be both necessary and sufficient to drive the pathological growth of cardiomyocytes in a murine model of left ventricular pressure overload. Based on the findings, we proposed that miR-132 may serve as a therapeutic target in heart failure therapy. Here we provide novel mechanistic insight and translational evidence for the therapeutic efficacy in small and large animal models (n=135) of heart failure. We demonstrate strong PK/PD relationship, dose-dependent efficacy and high clinical potential of a novel optimized synthetic locked nucleic acid phosphorothioate backbone antisense oligonucleotide inhibitor of miR-132 (antimiR-132) as a next-generation heart failure therapeutic.

2020-01-09 | PXD015337 | Pride

"Cancersensor": Circadian Rhythms

Project description:Observational, non randomized study aimed at measuring the circadian rhythms in the urinary concentrations of physiological modified nucleosides in 30 patients with metastatic colorectal cancer and in 30 age and sex-matched healthy subjects.

| 2132582 | ecrin-mdr-crc

Purinergic signaling in enteric gliosis [Dataset EV1]

Project description:Purinergic signaling in enteric gliosis [Dataset EV1]

| PRJNA556859 | ENA

Purinergic signaling in enteric gliosis [Dataset EV2]

Project description:Purinergic signaling in enteric gliosis [Dataset EV2]

| PRJNA556860 | ENA

Expressing data from endothelial cells overexpressing the purinergic receptor P2Y2

Project description:Purinergic P2 receptors are critical regulators of several functions within the vascular system, including platelet aggregation, vascular inflammation and vascular tone. A role for ATP release and P2Y receptors in angiogenesis has been implicated, however, the involvement of purinergic signalling in endothelial sprouting and vascular growth remains poorly understood. Here, we demonstrate that blood vessel growth is controlled by P2Y2 receptors. Inhibition of P2Y2 using a selective antagonist or modulation of P2Y2 receptor expression significantly influenced sprouting and vascular tube formation. Mechanistically, overexpression of P2Y2 in endothelial cells resulted in increased expression of the pro-angiogenic molecules CXCR4, CD34 and angiopoietin-2, while expression of Tie2 and VEGFR-2 decreased. Interestingly, elevated P2Y2 expression caused constitutive phosphorylation of ERK1/2 and VEGFR-2. However, stimulation of cells with the P2Y2 agonist UTP did not influence sprouting unless P2Y2 was constitutively expressed, indicating that enhanced receptor expression, and not activation, is the primary trigger for angiogenesis. Our data suggest that P2Y2 receptors have an essential function in angiogenesis through cross-talk of P2Y2 and VEGFR-2 and that P2Y2 may represent a therapeutic target to regulate blood vessel growth.

2019-07-04 | GSE133795 | GEO

Altered Circular RNA Expression in Patients with Repeated Implantation Failure

Project description:To evaluate differentially expressed circRNAs in patients with recurrent implantation failure, we used circRNA microarrays to screen circRNA expression profiles in endometrial biopsies from 6 women with recurrent implantation failure and controls. Our study revealed for the first time a unique set of circRNA expression signatures in the endometrial tissue of patients with repeated implantation failure, which may provide new molecular candidates for the diagnosis and clinical treatment of embryo implantation failure.

2022-08-28 | GSE212030 | GEO

CHO_library_B_GCN Screen

Project description:CHO_library_B_GCN Screen

| PRJNA556755 | ENA

CIRCADIAN RHYTHM REPROGRAMMING DURING LUNG INFLAMMATION/ Microarray Experiment #2

Project description:In this study we utilized a genome-wide approach to analyze circadian patterns of gene expression in mouse lung lungs, both in the basal state and in the setting of systemic inflammation caused by endotoxemia. We chose the lung because it represents a primary portal for systemic infection and organ failure in critically ill patients, and because the lung exhibits strong physiological circadian rhythms in health and in diseases such as asthma. The gene expression the data presented here was correlated to histological observations and metabolite measurements derived from the same biological samples, in order to obtain a broad picture of how inflammation impacts circadian rhythms in mouse lung.

2014-07-16 | GSE59404 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data